财报季|减重药物下半场:药王易主、定价压力与渗透为王

动脉新医药
Feb 06

近日,随着诺和诺德与礼来双双发布2025年财报,司美格鲁肽与替尔泊肽“药王”争夺故事正在进入新章节。诺和诺德2025年销售额达3091亿丹麦克朗(约合468.5亿美元,按2025年平均汇率计算:1丹麦克朗=0.1516美元,下同),以固定汇率计算增长10%。司美格鲁肽全系药物2025年全年销售额达到2282.88亿丹麦克朗(约合346.08亿美元)。降糖版司美格鲁肽注射液Ozempic销售额...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10